Evaluation of 3'-deoxy-3'-18F-fluorothymidine for monitoring tumor response to radiotherapy and photodynamic therapy in mice
- PMID: 15471845
Evaluation of 3'-deoxy-3'-18F-fluorothymidine for monitoring tumor response to radiotherapy and photodynamic therapy in mice
Abstract
3'-Deoxy-3'-18F-fluorothymidine (18F-FLT) has been suggested as a new PET tracer for imaging tumor proliferation. We investigated the use of 18F-FLT to monitor the response of tumors to radiotherapy and photodynamic therapy (PDT) in mice.
Methods: C3H/He mice bearing an SCCVII tumor were treated with single-dose x-ray irradiation of 20 Gy. Tumor uptake was examined for 18F-FLT, 3H-thymidine (3H-Thd), 18F-FDG, and 14C-deoxyglucose (14C-DG) at 6 h, 12 h, 24 h, 3 d, and 7 d after radiotherapy. BALB/c nu/nu mice bearing a HeLa tumor were treated with PDT. Tumor uptake was examined for the 4 tracers at 24 h after PDT. Expression of proliferating cell nuclear antigen (PCNA) was determined in untreated and treated tumors.
Results: In the biodistribution study, considerable uptake of 18F-FLT was observed in both tumor types. Tumor volumes decreased to 39.3% +/- 22.4% at 7 d after radiotherapy. The PCNA labeling index was reduced in x-ray-irradiated tumors (control, 53.2% +/- 8.7%; 6 h, 38.5% +/- 5.3%; 24 h after radiotherapy, 36.8% +/- 5.3%). 18F-FLT uptake in tumor expressed as the percentage of the injected dose per gram of tumor (%ID/g) decreased significantly at 6 h and remained low until 3 d after radiotherapy (control, 9.7 +/- 1.2 %ID/g; 6 h, 5.9 +/- 0.4 %ID/g; 24 h, 6.1 +/- 1.3 %ID/g; 3 d after radiotherapy, 6.4 +/- 1.1 %ID/g). 18F-FDG uptake tended to gradually decrease but a significant decrease was found only at 3 d (control, 12.1 +/- 2.7 %ID/g; 6 h, 13.3 +/- 2.3 %ID/g; 24 h, 8.6 +/- 1.8 %ID/g; 3 d after radiotherapy, 6.9 +/- 1.2 %ID/g). PDT resulted in a reduction of the PCNA labeling index (control, 82.0% +/- 8.6%; 24 h after PDT, 13.5% +/- 12.7%). Tumor uptake of 18F-FLT decreased (control, 11.1 +/- 1.3 %ID/g; 24 h after PDT, 4.0 +/- 2.2 %ID/g), whereas 18F-FDG uptake did not decrease significantly after PDT (control, 3.5 +/- 0.6 %ID/g; 24 h after PDT, 2.3 +/- 1.1 %ID/g). Changes in the uptake of 18F-FLT and 18F-FDG were similar to those of 3H-Thd and 14C-DG, respectively.
Conclusion: In our model system, changes in 18F-FLT uptake after radiotherapy and PDT were correlated with those of 3H-Thd and the PCNA labeling index. The decrease in 18F-FLT uptake after treatments was more rapid or pronounced than that of 18F-FDG. Therefore, 18F-FLT may be a feasible PET tracer for monitoring response to therapy in oncology.
Similar articles
-
[Correlation of 3'-deoxy-3'-18F-fluorothymidine uptake to cell proliferation in lung carcinoma xenografts].Ai Zheng. 2006 Dec;25(12):1512-6. Ai Zheng. 2006. PMID: 17166377 Chinese.
-
3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography.Cancer Res. 2003 Jul 1;63(13):3791-8. Cancer Res. 2003. PMID: 12839975
-
Evaluation of D-18F-FMT, 18F-FDG, L-11C-MET, and 18F-FLT for monitoring the response of tumors to radiotherapy in mice.J Nucl Med. 2009 Feb;50(2):290-5. doi: 10.2967/jnumed.108.057091. Epub 2009 Jan 21. J Nucl Med. 2009. PMID: 19164228
-
[Is 3'-deoxy-3'- [18F] fluorothymidine ([18F]-FLT) the next tracer for routine clinical PET after R [18F]-FDG?].Bull Cancer. 2005 Sep;92(9):789-98. Bull Cancer. 2005. PMID: 16203269 Review. French.
-
[18F]FLT-PET in oncology: current status and opportunities.Eur J Nucl Med Mol Imaging. 2004 Dec;31(12):1659-72. doi: 10.1007/s00259-004-1687-6. Eur J Nucl Med Mol Imaging. 2004. PMID: 15565331 Review.
Cited by
-
Early assessment of therapy response in malignant lymphoma with the thymidine analogue [18F]FLT.Eur J Nucl Med Mol Imaging. 2007 Nov;34(11):1775-82. doi: 10.1007/s00259-007-0452-z. Epub 2007 May 31. Eur J Nucl Med Mol Imaging. 2007. PMID: 17541585
-
Imaging and photodynamic therapy: mechanisms, monitoring, and optimization.Chem Rev. 2010 May 12;110(5):2795-838. doi: 10.1021/cr900300p. Chem Rev. 2010. PMID: 20353192 Free PMC article. Review. No abstract available.
-
Acute cytotoxic effects of photoimmunotherapy assessed by 18F-FDG PET.J Nucl Med. 2013 May;54(5):770-5. doi: 10.2967/jnumed.112.112110. Epub 2013 Mar 27. J Nucl Med. 2013. PMID: 23536226 Free PMC article.
-
Clinical relevance of imaging proliferative activity in lung nodules.Eur J Nucl Med Mol Imaging. 2005 May;32(5):525-33. doi: 10.1007/s00259-004-1706-7. Epub 2004 Dec 14. Eur J Nucl Med Mol Imaging. 2005. PMID: 15599526 Clinical Trial.
-
18F-FDG PET/CT for image-guided and intensity-modulated radiotherapy.J Nucl Med. 2009 Oct;50(10):1655-65. doi: 10.2967/jnumed.108.055780. Epub 2009 Sep 16. J Nucl Med. 2009. PMID: 19759099 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous